New Two-Target cell therapy tested for Tough-to-Treat blood cancers
NCT ID NCT06986434
Summary
This early-phase study is testing a new type of CAR-T cell therapy designed to target two markers (CD19 and BCMA) on cancer cells. It aims to see if this treatment is safe and effective for adults with advanced plasma cell cancers, like multiple myeloma, that have come back or stopped responding to standard treatments. The study will enroll about 20 patients to monitor side effects and how well the cancer responds.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the Fifth Medical Center of Chinese People's Liberation Army General Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.